#United States #New York #Immunotherapy #Cancer Vaccine #melanoma

Significant Decrease in Melanoma Recurrence with New Vaccine Treatment

Recent findings from a study led by NYU Langone Health reveal a promising breakthrough in cancer treatment, indicating that a combination of a personalized vaccine and a standard immunotherapy drug significantly lowers the risk of melanoma recurrence. This study, presented at the 2026 American Society of Clinical Oncology annual meeting, highlights a 49% reduction in the risk of recurrence and death among melanoma patients who have undergone surgery to remove their tumors.

The trial involved 107 patients who received a unique vaccine, termed intismeran, along with pembrolizumab (commonly known as Keytruda), an established immunotherapy. This combination was contrasted with data gathered from a separate group of 50 patients who were treated solely with pembrolizumab. The results were striking: 68.8% of patients receiving the combination therapy remained free of cancer after five years, compared to 49.1% in the other group. Moreover, the combination therapy led to a staggering 59% reduction in the risk of distant metastasis, or the spread of cancer to other parts of the body.

Dr. Janice Mehnert, a senior investigator and professor at NYU Grossman School of Medicine, expressed optimism regarding these results, noting that the implementation of intismeran alongside immunotherapy appears to significantly improve clinical outcomes for melanoma patients. This research holds promise not just for melanoma treatment but also for other cancers that exhibit high mutation rates and challenge current therapeutic approaches.

The core of this innovative treatment lies in the way intismeran is tailored from each patient's unique tumor profile, enabling it to target specific cancer cell antigens. These antigens, known as neoantigens, trigger a robust immune response, enhancing the body’s ability to recognize and attack aberrant cells. By using mRNA technology, the vaccine equips T cells—the body’s primary defenders against infections and cancers—to actively seek out and destroy melanoma cells exhibiting these neoantigens.

In this study, as all participants had their tumors surgically excised prior to the trial, researchers were adept at analyzing the patients' cells for specific neoantigens and crafting a personalized vaccine to suit each individual.

While the results are encouraging, Dr. Mehnert emphasized that the journey doesn't end here. A phase 3 multicenter trial is already underway to analyze the efficacy of intismeran as a first-line treatment combined with pembrolizumab for melanoma. Additionally, researchers are exploring the potential of this vaccine in preventing recurrence for lung and other cancers.

The trial enrolled participants from cancer centers in both the United States and Australia between 2019 and 2021, showcasing a diverse patient demographic. Notably, common adverse effects from the combined treatment were deemed manageable, including fatigue, injection site pain, and chills.

As skin cancer remains the most prevalent form of cancer in the United States, with projected new cases reaching around 112,000 in 2026, advancements like this offer a beacon of hope for improved patient outcomes. Funding was provided by Moderna, the manufacturer of the vaccine, and Merck, known for pembrolizumab. The research team included a broad array of experts from various institutions, underscoring the collaborative effort in the fight against cancer.

In conclusion, the findings from this pivotal study not only enhance the landscape of melanoma treatment but also potentially pave the way for innovative combinations of mRNA vaccines and immunotherapies against various other malignancies.